# Safety and Efficacy of ALV003 for the Treatment of Celiac Disease

> **NCT00959114** · PHASE2 · COMPLETED · sponsor: **Alvine Pharmaceuticals Inc.** · enrollment: 74 (actual)

## Conditions studied

- Celiac Disease

## Interventions

- **BIOLOGICAL:** ALV003
- **BIOLOGICAL:** ALV003 placebo

## Key facts

- **NCT ID:** NCT00959114
- **Lead sponsor:** Alvine Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2010-08
- **Final completion:** 2010-10
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2012-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00959114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00959114, "Safety and Efficacy of ALV003 for the Treatment of Celiac Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00959114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*